← Back to screener

RELMADA THERAPEUTICS, INC. RLMD

Rank #2229 · Nasdaq · $0.4B market cap
⚠ Going-concern flag — the auditor (CBIZ CPAs P.C.) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
28.4
P/E
-4.7
P/B
4.40
ROE
-93.7%
Op. Margin
–%
Debt Ratio
12%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -4.7x, P/B 4.40x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -93.7%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 12%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2013$0.0B$-0.0B$-0.0B$0.0B-151.885
2015–$-0.0B$-0.0B$-0.0B–-724
2016–$-0.0B$-0.0B$-0.0B–-1405
2017–$-0.0B$-0.0B$0.0B–36
2018–$-0.0B$-0.0B$0.0B–20
2019–$-0.0B$-0.0B$0.0B–586
2020–$-0.0B$-0.0B$-0.0B–-47
2021–$-0.1B$-0.1B$0.1B–11
2022–$-0.1B$-0.1B$0.1B–14
2023–$-0.2B$-0.2B$0.2B–6
2024–$-0.1B$-0.1B$0.1B–9
2025–$-0.1B$-0.1B$0.1B–12

← See the full screener